Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
All content curated by
Published in Oncology

Journal Scan / Research · February 20, 2022

Follow-Up of Patients With Relapsed/Refractory FLT3 Mutation–Positive AML Treated With Gilteritinib

Blood

 

Additional Info

Blood
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial
Blood 2022 Jan 26;[EPub Ahead of Print], AE Perl, RA Larson, NA Podoltsev, SA Strickland, ES Wang, E Atallah, GJ Schiller, G Martinelli, A Neubauer, J Sierra, P Montesinos, C Récher, SS Yoon, N Hosono, M Onozawa, S Chiba, HJ Kim, N Hasabou, Q Lu, R Tiu, MJ Levis

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading